Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines.
Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines.
复制标题
SARS-CoV-2 中和广度与异源初免-加强疫苗接种顺序的关联
DOI：
10.1016/j.medj.2022.05.003
复制
发表时间：
2022-08-12
期刊：
影响因子：
17
通讯作者：
Hong, Peng
中科院分区：
文献类型：
--
作者：
Zhu, Yufan;Lu, Yingyin;Zhou, Cail;Tong, Ganglin;Gao, Manman;Zhan, Yan;Wang, Yan;Liang, Ran;Li, Yawei;Gao, Tianjiao;Wang, Li;Zhang, Muyun;Cheng, Jin;Gong, Jun;Wang, Jimin;Zhang, Wei;Qi, Junhua;Cui, Miao;Zhu, Longchao;Xiao, Fenglian;Zhu, Linyu;Xu, Yunsheng;Zheng, Zhihua;Zhou, Zhiyu;Cheng, Zhengjiang;Hong, Peng
新的证据表明，异源初免加强 COVID-19 疫苗接种是比同源疫苗接种更优越的策略。动物实验和临床观察表明，异种疫苗接种后，针对流感病毒变异体的抗体反应增强；然而，COVID-19 疫苗在初免-加强方案中的接种顺序是否会影响针对 SARS-CoV-2 变体的抗体反应尚不清楚。我们对一组最近在同源或异源初免-加强方案下接种了三种灭活 COVID-19 疫苗的医护人员 (n = 486) 进行了免疫学分析。通过总抗体测量、替代病毒中和试验和假病毒中和试验 (PNA) 评估针对祖先 SARS-CoV-2 (Wuhan-Hu-1) 的抗体反应。此外，还通过 PNA 测量了针对所关注的 SARS-CoV-2 变体的血清中和活性。我们观察到，在异源 BBIBP-CorV/CoronaVac 和 WIBP-CorV/CoronaVac 接受者中，针对广泛传播的 SARS-CoV-2 变体 B.1.617.2 的血清中和活性最强。相反，CoronaVac/BBIBP-CorV 和 CoronaVac/WIBP-CorV 的接受者表现出比反向方案的接受者显着更低的 B.1.617.2 中和滴度。实验室测试显示，针对常见变体而非祖先 SARS-CoV-2 的中和活性与异源初免-加强疫苗的接种顺序相关。在调整已知的混杂因素后，多变量回归分析证实了这种关联。我们的数据提供了异源初免加强疫苗接种者中针对 SARS-CoV-2 的中和广度依赖于接种顺序的扩展的临床证据，并呼吁进一步研究其潜在机制。中国国家重点研发计划、中国国家发展和改革委员会、中国国家自然科学基金委员会、深圳市科创委和美国退伍军人事务部。出于各种原因，世界各地许多人在两剂疫苗接种计划中接种了不同类型的 COVID-19 疫苗。然而，尚不清楚此类异源疫苗的接种顺序是否与随后的免疫反应相关。在这里，一个由来自中国和美国的医生和科学家组成的国际团队对一组医护人员进行了研究，他们是最早接受异源 COVID-19 疫苗接种的人之一。作者发现，异源疫苗的接种顺序与中和 SARS-CoV-2 变体的能力有关，但与疫苗所基于的原始毒株无关。结果表明，使用高效异源加强疫苗可能是引发针对未来变异的保护性免疫力的一种经济有效的方法。朱等人。研究人员对接受过同源或异源 COVID-19 初免加强疫苗接种的医护人员进行了研究，发现异源疫苗的接种顺序与针对 SARS-CoV-2 变体的血清中和广度相关。研究结果表明，使用高效异源加强疫苗作为针对未来变种的经济有效的策略。
Emerging evidence suggests heterologous prime-boost COVID-19 vaccination as a superior strategy than homologous schedules. Animal experiments and clinical observations have shown enhanced antibody response against influenza variants after heterologous vaccination; however, whether the inoculation order of COVID-19 vaccines in a prime-boost schedule affects antibody response against SARS-CoV-2 variants is not clear. We conducted immunological analyses in a cohort of health care workers (n = 486) recently vaccinated by three types of inactivated COVID-19 vaccines under homologous or heterologous prime-boost schedules. Antibody response against ancestral SARS-CoV-2 (Wuhan-Hu-1) was assessed by total antibody measurements, surrogate virus neutralization tests, and pseudovirus neutralization assays (PNA). Furthermore, serum neutralization activity against SARS-CoV-2 variants of concern was also measured by PNA. We observed strongest serum neutralization activity against the widely circulating SARS-CoV-2 variant B.1.617.2 among recipients of heterologous BBIBP-CorV/CoronaVac and WIBP-CorV/CoronaVac. In contrast, recipients of CoronaVac/BBIBP-CorV and CoronaVac/WIBP-CorV showed significantly lower B.1.617.2 neutralization titers than recipients of reverse schedules. Laboratory tests revealed that neutralizing activity against common variants but not the ancestral SARS-CoV-2 was associated with the inoculation order of heterologous prime-boost vaccines. Multivariable regression analyses confirmed this association after adjusting for known confounders. Our data provide clinical evidence of inoculation order-dependent expansion of neutralizing breadth against SARS-CoV-2 in recipients of heterologous prime-boost vaccination and call for further studies into its underlying mechanism. National Key R&D Program of China, National Development and Re-form Commission of China, National Natural Science Foundation of China, Shenzhen Science and Technology Innovation Commission, and US Department of Veterans Affairs. Many people around the world have received different types of COVID-19 vaccines in their two-dose vaccination schedules for various reasons. However, it is not clear whether the inoculation order of such heterologous vaccines was associated with subsequent immune responses. Here, an international team of physicians and scientists from China and the United States studied a cohort of healthcare workers who were among the earliest recipients of heterologous COVID-19 vaccination. The authors found that the inoculation order of heterologous vaccines was associated with the capability of neutralizing SARS-CoV-2 variants but not the original strain that the vaccines were based on. The results suggested that using heterologous booster vaccines with high potency could be a cost-efficient way to elicit protective immunity against future variants. Zhu et al. studied healthcare workers who had received homologous or heterologous prime-boost COVID-19 vaccination to find that the inoculation order of heterologous vaccines was associated with serum neutralization breadth against SARS-CoV-2 variants. The findings suggested using heterologous booster vaccines with high potency as a cost-efficient strategy against future variants.
登录
查看更多内容
影响因子：
64.5
作者：
Liu C;Ginn HM;Dejnirattisai W;Supasa P;Wang B;Tuekprakhon A;Nutalai R;Zhou D;Mentzer AJ;Zhao Y;Duyvesteyn HME;López-Camacho C;Slon-Campos J;Walter TS;Skelly D;Johnson SA;Ritter TG;Mason C;Costa Clemens SA;Gomes Naveca F;Nascimento V;Nascimento F;Fernandes da Costa C;Resende PC;Pauvolid-Correa A;Siqueira MM;Dold C;Temperton N;Dong T;Pollard AJ;Knight JC;Crook D;Lambe T;Clutterbuck E;Bibi S;Flaxman A;Bittaye M;Belij-Rammerstorfer S;Gilbert SC;Malik T;Carroll MW;Klenerman P;Barnes E;Dunachie SJ;Baillie V;Serafin N;Ditse Z;Da Silva K;Paterson NG;Williams MA;Hall DR;Madhi S;Nunes MC;Goulder P;Fry EE;Mongkolsapaya J;Ren J;Stuart DI;Screaton GR
通讯作者：
Screaton GR
影响因子：
7.8
作者：
Khong KW;Liu D;Leung KY;Lu L;Lam HY;Chen L;Chan PC;Lam HM;Xie X;Zhang R;Fan Y;To KK;Chen H;Yuen KY;Chan KH;Hung IF
通讯作者：
Hung IF
化学发光微粒免疫分析法在 SARS-CoV-2 感染诊断中的临床应用。
影响因子：
8.8
作者：
Liu, Wanbing;Kou, Guomei;Zheng, Shangen
通讯作者：
Zheng, Shangen
影响因子：
82.9
作者：
Schmidt T;Klemis V;Schub D;Mihm J;Hielscher F;Marx S;Abu-Omar A;Ziegler L;Guckelmus C;Urschel R;Schneitler S;Becker SL;Gärtner BC;Sester U;Sester M
通讯作者：
Sester M
DOI：
10.1056/nejmoa2105000
发表时间：
2021-06-10
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hacisuleyman E;Hale C;Saito Y;Blachere NE;Bergh M;Conlon EG;Schaefer-Babajew DJ;DaSilva J;Muecksch F;Gaebler C;Lifton R;Nussenzweig MC;Hatziioannou T;Bieniasz PD;Darnell RB
通讯作者：
Darnell RB